Immunotherapy News and Research

Latest Immunotherapy News and Research

Full tumor DNA sequencing becomes standard for children with cancer

Readouts of the full DNA of children with cancer at diagnosis have been implemented as the standard of care in a European first.

19 Jun 2025

OCCAM Immune and Cancer Research Institute join forces to advance immunotherapy

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on understanding the immune system's role in disease-is partnering with the Cancer Research Institute (CRI) to unlock the secrets of how the immune system responds to advanced therapies.

17 Jun 2025

Rare pancreatic cancer patients show remarkable outcomes with immunotherapy

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence."

17 Jun 2025

Breakthrough therapy targets aggressive bladder cancer variant

Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.

17 Jun 2025

Researchers identify a new treatment strategy for neuroblastoma

Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer.

16 Jun 2025

New computational tool uncovers hidden genetic mutations in proteins

Scientists at UCLA and the University of Toronto have developed an advanced computational tool, called moPepGen, that helps identify previously invisible genetic mutations in proteins, unlocking new possibilities in cancer research and beyond.

16 Jun 2025

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

15 Jun 2025

Advancing precision oncology in intrahepatic cholangiocarcinoma

ICCA accounts for 10–15% of primary liver cancers and is notorious for late-stage diagnosis and resistance to chemotherapy and radiotherapy.

13 Jun 2025

Bringing microbiome science into everyday clinical care

The article summarizes results of research and possible future clinical applications of the microbiome and provides instructions for doctors.

13 Jun 2025

Boosting CAR T cell survival to improve solid tumor therapy

Chimeric Antigen Receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell therapy is the ability of these cells to survive long enough to target the entire tumor.

13 Jun 2025

Cholesterol shields cancer cells from heat treatment in hyperthermia therapy

Hyperthermia, a cancer treatment using controlled heat to kill tumor cells, shows promise but faces limitations due to some tumor cells' unexpected heat resistance.

12 Jun 2025

New cancer vaccine shows promise against deadly pancreatic tumors

Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer Society.

11 Jun 2025

Targeting metabolic reprogramming in breast cancer treatment

Breast cancer remains the most prevalent malignancy among women worldwide, posing a critical challenge to global health.

11 Jun 2025

Eva1 targeted CAR T cells successfully eliminate tumors in preclinical study

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya University in Japan and their collaborators have developed new CAR-T cells to target malignant tumors.

11 Jun 2025

Study reveals a unique vulnerability in melanoma patients with neurofibromin 1 mutations

Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a new study shows.

10 Jun 2025

Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections

Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the publication of a peer-reviewed study in The Journal of Immunology.

10 Jun 2025